Sydbank share buyback programme: transactions in week 19
Company AnnouncementNo21/2022 | Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 Fax +45 74 37 35 36 Sydbank A/S CVR No DK 12626509, Aabenraa sydbank.dk |
| 16 May 2022 |
Dear Sirs
Sydbank share buyback programme: transactions in week 19
On 2 March 2022 Sydbank announced a share buyback programme of DKK 425m. The share buyback commenced on 7 March 2022 and will be completed by 30 December 2022.
The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules.
The following transactions have been made under the share buyback programme:
| Number of shares | VWAP | Gross value (DKK) | |
| Accumulated, most recent announcement | 379,000 | 87,993,230.00 | |
| 09 May 2022 10 May 2022 11 May 2022 12 May 2022 13 May 2022 (public holiday) | 12,000 12,000 12,000 18,000 - | 232.87 232.01 228.73 225.11 - | 2,794,440.00 2,784,120.00 2,744,760.00 4,051,980.00 - |
| Total over week 19 | 54,000 | 12,375,300.00 | |
| Total accumulated during the share buyback programme | 433,000 | 100,368,530.00 |
All transactions were made under ISIN DK 0010311471 and effected by Danske Bank A/S on behalf of Sydbank A/S. Further information about the transactions, cf Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse and the Commission delegated regulation, is available in the attachment.
Following the above transactions, Sydbank holds a total of 442,500 own shares, equal to 0.75% of the Bank’s share capital.
Yours sincerely
Karen Frøsig Bjarne Larsen
CEO Deputy Group Chief Executive
Attachment
© 2022 GlobeNewswire, Inc. All Rights Reserved.
NRx Pharmaceuticals (Nasdaq: NRXP): FDA Declines Emergency Use Authorization for ZYESAMI (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
